ArticleSaudi medical journal2020
Nitric oxide, asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine levels in psychotic exacerbation of schizophrenia and bipolar disorder manic episode.
Article in Saudi medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A systematic review and meta-analysis of nitric oxide-associated arginine metabolites in schizophrenia.Translational psychiatry · 2024Pooled it
- UntargetedTranslational psychiatry · 2026Article
- The Emerging Role of the DDAH Proteins in Psychiatric Disorders.Biological psychiatry global open science · 2025Review
- Investigating seasonal metabolic variations in bipolar disorder: a targeted metabolomics study.BMC psychiatry · 2025Article
- Oxidative and nitrosative stress in bipolar affective disorder and its familial aggregation.Indian journal of psychiatry · 2025Article
- The molecular mechanism of nitric oxide in memory consolidation and its role in the pathogenesis of memory-related disorders.Neurogenetics · 2025Review
- A comparison of asymmetric dimethylarginine, arginine, galectin-3, and echocardiographic data with bipolar disorder and schizophrenia.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Arginine metabolism and neurocognitive impairment in offspring of bipolar parents: a high-risk case-control study.Frontiers in psychiatry · 2025Article
- Arginine metabolomics in mood disorders.Heliyon · 2024Article
- Evaluation of Asymmetric Dimethylarginine, Malondialdehyde, and Vitamin Levels of Borderline Personality Disorder Patients With and Without Self-Mutilation.Psychiatry investigation · 2023Article
- Metabolomics of cerebrospinal fluid reveals prognostic biomarkers in pediatric status epilepticus.CNS neuroscience & therapeutics · 2023Article
- Knock-out of the critical nitric oxide synthase regulator DDAH1 in mice impacts amphetamine sensitivity and dopamine metabolism.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Divergent Dimethylarginine Dimethylaminohydrolase Isoenzyme Expression in the Central Nervous System.Cellular and molecular neurobiology · 2022Article
- Pro/Antioxidant State as a Potential Biomarker of Schizophrenia.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine the changes in nitric oxide (NO), asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-arginine levels in schizophrenia during acute psychotic exacerbation and in bipolar disorder during mania and to compare those changes to healthy controls.
methodsThirty schizophrenia patients with acute psychotic exacerbation and 30 bipolar disorder patients with mania, who attended the Psychiatry Department, Erenköy Hospital for Mental and Nervous Diseases, Istanbul, Turkey, in 2010. Thirty healthy controls were included. The diagnosis was made using the Structured Clinical Interview for Axis I Disorders (SCID-I) interviews. Patients' demographic data were recorded, and NO, SDMA, L-arginine, and ADMA levels were studied.
resultsNitric oxide levels in schizophrenia patients were significantly lower than the control group. Nitric oxide levels in the bipolar group were lower than the control group but the difference was not statistically significant. The levels of SDMA, ADMA, and L-arginine were found to be significantly higher in schizophrenia and bipolar disorder patients than the control group. The disease duration was slightly negatively correlated with NO levels in bipolar patients. In schizophrenia patients, the disease severity was slightly positively correlated with NO levels.
conclusionSignificant changes in NO, SDMA, ADMA, and L-arginine levels in schizophrenia and bipolar disorder patients suggest that NO and inhibitors of NO might be implicated in the neurobiology of schizophrenia and bipolar disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.